Drug Profile
Insulin oral - Puredel
Alternative Names: OssulinLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Puredel
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Diabetes-mellitus in United Kingdom (PO)
- 13 Nov 2009 Puredel intends to out-licence Ossulin™ after proof of principle studies (http://www.cmdpharmaltd.com/ossulin.asp)
- 13 Nov 2009 Clinical trials in Diabetes mellitus in United Kingdom (PO)